

(51) International Patent Classification:
C07K 16/28 (2006.01)(21) International Application Number:
PCT/US2015/043723(22) International Filing Date:
5 August 2015 (05.08.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2014/083715 5 August 2014 (05.08.2014) CN

(72) Inventors; and

(71) Applicants : ZHA, Jiping [US/CN]; Crown Bioscience Inc., 6 Beijing West Road, Taicang Economic Development Area, Jiangsu, 215400 (CN). SUN, Ziyong [US/CN]; Crown Bioscience Inc., 6 Beijing West Road, Taicang Economic Development Area, Jiangsu, 215400 (CN). QIU, Junzhuan [CN/CN]; Crown Bioscience Inc., 6 Beijing West Road, Taicang Economic Development Area, Jiangsu, 215400 (CN).

(74) Agents: WU, Nan et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW Suite 700, Washington, District of Columbia 20004-2400 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

[Continued on next page]

(54) Title: ANTI-PD-L1 ANTIBODIES

Figure 1



(57) Abstract: The present disclosure relates to antibodies and antigen-binding fragments thereof that bind to PD-L1, and to methods of using such antibodies and antigen-binding fragments. For example, the present invention provides humanized anti-PD-L1 antibodies and methods of use thereof.



— with sequence listing part of description (Rule 5.2(a))